Oncolytic Virotherapy Market – Virus Type (Genetically Engineered Oncolytic, Oncolytic Wild-type), Application (Solid Tumors, Melanoma), End user (Hospitals, Specialty Clinics, Cancer Research Institutes) – Global Forecast (2024 – 2032)

Oncolytic Virotherapy Market Size

Oncolytic Virotherapy Market size was valued at USD 20.1 million in 2023 and is anticipated to showcase growth at 26.9% CAGR from 2024 and 2032. Rising incidence of cancer, growing approvals for oncolytic therapy for treating rare cancers, and increasing investments for developing new oncolytic virotherapies are driving the revenue growth in market. Additionally, growing focus towards combination therapies is also driving the market.
 

Oncolytic virotherapy is a form of cancer treatment that uses viruses to selectively infect, replicate within, and destroy cancer cells while sparing normal cells. Oncolytic viruses are typically engineered to target and replicate in tumor cells, leading to their destruction through direct lysis, induction of apoptosis, or through stimulating the immune system's anti-tumor response.

Oncolytic virotherapy Market Trends

• The market is experiencing a growing interest in combination therapy. Vendors are combining oncolytic virotherapy with other cancer immunotherapy, such as immune checkpoint inhibitors, to enhance anti-tumor immune responses and overcome resistance mechanisms.
   
• Combination therapies are gaining interest of researchers to enhance immune system activation and enhance treatment results across various types of cancer. For instance, according to a study published by National Center for Biotechnology Information in January 2023, combining oncolytic viruses with anti?checkpoint antibodies can lead to improved antitumor responses. As a result, increasing interest from researchers in combination therapy is expected to drive the market growth during the forecast period.
   
• Moreover, global market is also experiencing growth due to rising clinical trial engagement and commercialization initiatives extending beyond conventional developed markets. Emerging regions in Asia and Latin America have become key contributors to the advancement and acceptance of oncolytic virotherapy.
   

Oncolytic Virotherapy Market Analysis

Based on virus type, the oncolytic virotherapy market is segmented into genetically engineered oncolytic viruses and oncolytic wild-type viruses. The genetically engineered oncolytic viruses segment has been further sub-segmented into adenovirus, herpes simplex virus, vaccinia virus. similarly, the oncolytic wild-type viruses segment has been further sub-segmented into reovirus, vesicular stomatitis virus, newcastle disease virus. The genetically engineered oncolytic viruses segment held the majority of market share in 2023 and is anticipated to grow at CAGR of 27.3% over the coming years.
 

• The leading share of genetically engineered oncolytic viruses can be attributed to their enhanced specificity and targeting capabilities. Genetically engineered viruses such as adenovirus and herpes simplex virus can be designed to target and infect cancer cells specifically, without impacting healthy cells. Owing to their target specificity, majority of researchers are focusing towards using genetically engineered oncolytic viruses, which is contributing towards the growth of the segment.
   
• Moreover, genetic engineered oncolytic viruses can be modified through incorporating additional therapeutic genes into the virus, enhancing its overall anti-cancer activity. As a result, they offer improved efficacy and efficient treatment outcomes. These benefits are fueling the adoption of genetic engineered oncolytic viruses across in market.
   

Based on application, the oncolytic virotherapy market is classified into solid tumors and melanoma. Solid tumors are further segmented into breast cancer, prostate cancer, lung cancer, and glioblastoma. Similarly, melanoma is further segmented into leukemia, lymphoma, myeloma, and hematological malignancies. The solid tumors segment dominated the market with a revenue of about USD 12.1 million in 2023.
 

• Leading share of solid tumor segment can be attributed to high prevalence of breast, prostate, and lung cancer. For instance, according to the World Health Organization, in 2022, about 2.3 million women were diagnosed with breast cancer. The high prevalence of breast cancer is driving the demand for oncolytic virotherapy in solid tumor segment, which is driving the overall growth of the segment.
   
• Furthermore, once the chemotherapy and surgery are unsuccessful, there are limited treatment options for patients with solid tumors. This has also propelled the investments for developing new cancer therapies such as oncolytic virotherapies, thereby driving the revenue growth in the segment.

Based on end-user, the oncolytic virotherapy market is classified into hospitals, specialty clinics, cancer research institutes. The hospitals segment secured a leading share of about 65.6% in 2023 and is anticipated to grow at 26.7% CAGR during the forecast period.
 

• Increasing preference for inpatient settings to avail cancer therapies is driving the revenue growth in hospitals segment. Inpatient settings such as hospitals have specialized oncology departments with skilled healthcare professionals, including radiation oncologists, medical oncologists, and surgical oncologists, who have a significant experienced in diagnosing and treating cancer patients.
   
• Moreover, the rising utilization of combination treatments, which involves a collaborative approach wherein patients undergo oncolytic virotherapy alongside chemotherapy, radiation therapy, and surgical interventions, is further bolstering the preference for hospitals among patients. Hospitals are well-equipped to manage and monitor combination therapies as they offer comprehensive care through multidisciplinary care teams.
   

North America oncolytic virotherapy market accounted for 42.1% of market share in global market in 2023 and is predicted to reach USD 68.9 million by 2032.
 

• Leading share of North America can be attributed to its robust research infrastructure. Leading pharmaceutical companies, academic institutions, and research centers actively contribute to the development and commercialization of oncolytic virotherapy in this region.
   
• Furthermore, early adoption of innovative therapies, including oncolytic virotherapy is also supporting the revenue growth for market in the region. Presence of advanced healthcare ecosystem and proactive approach to new treatments among cancer patients, due to rising awareness for high efficacy of viral therapies is increasing the adoption of oncolytic virotherapy in North America.
   

The U.S. oncolytic virotherapy market was valued at USD 7.3 million in 2023 and is anticipated to grow at a CAGR of 26.5% over the forecast period.

• High investments by vendors to accelerate research and developments in their pipeline technologies has contributed to an increased availability of oncolytic viral platforms in the U.S. For instance, in December 2022, Adstiladrin received approved from U.S. FDA, for use in patients with high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer. Availability of new oncolytic virotherapy platforms is further accelerating the revenue growth in the market.
   
• Moreover, the U.S. boasts a robust infrastructure for conducting clinical trials through utilizing its large network of hospitals, academic medical centers, and research organizations that actively recruit patients for oncolytic virotherapy trials. Availability of robust clinical infrastructure is helping the companies to accelerate their clinical developments in oncolytic virotherapy.
   
• Additionally, FDA's accelerated approval pathways and orphan drug designation to many pipelines under clinical stages have boosted the availability of oncolytic virotherapy treatments for rare cancers in the U.S.
   

Germany oncolytic virotherapy market is expected to show lucrative growth during the forecast period.
 

• Increasing growth in pre-clinical research programs for developing new oncolytic virus platforms such as measles vaccine virus, oncolytic adenoviruses, and parvoviruses platform are expected to surge the availability of oncolytic virotherapies in Germany.
   
• Moreover, growing availability of dedicated research facilities for developing new cancer therapies such as National Cancer Prevention Center and German Cancer Research Center is also expected to contribute to an accelerated research and development activities in market in Germany during the forecast period.
   

India oncolytic virotherapy market is anticipated to grow remarkably over the coming years.
 

• Increasing prevalence of cancer along with growing support from government to develop advanced cancer care capabilities is driving the revenue growth in the market in India. For instance, in December 2023, the central government implemented the strengthening of tertiary care cancer facilities scheme under the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD) such as cancer.
   
• Additionally, India has become a preferred location for clinical trials due to its well-established clinical research infrastructure, large patient population, and supportive regulatory environment. As a result, an increasing growth in clinical research in the country is expected to ensure an increasing availability of new oncolytic virotherapies in the country.
   

Oncolytic Virotherapy Market Share

The oncolytic virotherapy industry is moderately fragmented due to the requirement for high capital investments for research and development of oncolytic virus platform. The established vendors have substantial financial and human resources required to conduct capital intensive clinical trials and develop new oncolytic virotherapies, which contributes to their leading market share. The vendors compete in terms of efficacy and early approval and commercialization of their oncolytic virotherapy products.  
 

Oncolytic Virotherapy Market Companies

Prominent players operating in the oncolytic virotherapy industry include:

• Amgen Inc.
• BioVex, Inc.
• Circio Holding ASA 
• Daiichi Sankyo Company
• DNAtrix
• Lokon Pharma AB
• Medigene AG
• Oncolytics Biotech Inc.
• PsiOxus Therapeutics
• Shanghai Sunway Biotech Co., Ltd.
• SillaJen, Inc.
• Sorrento Therapeutics
• Theriva Biologics 
• Transgene SA
• Virogin Biotech 
   

Oncolytic Virotherapy Industry News:

• In January 2023, Theriva Biologics announced that the U.S. FDA has granted an orphan drug designation to VCN-01, an oncolytic adenovirus for the treatment of patients with pancreatic cancer.
   
• In October 2021, Virogn Biotech announced that the U.S. FDA has granted an orphan drug designation to its Class I innovative oncolytic virus product, VG161, for the treatment of Intrahepatic Cholangiocarcinoma.
   

The oncolytic virotherapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Virus Type

• Genetically engineered oncolytic viruses 
  • Adenovirus
  • Herpes simplex virus
  • Vaccinia virus
• Oncolytic wild-type viruses
  • Reovirus
  • Vesicular stomatitis virus
  • Newcastle disease virus

Market, By Application

• Solid tumors 
  • Breast cancer
  • Prostate cancer
  • Lung cancer
  • Glioblastoma
• Melanoma     
  • Leukemia
  • Lymphoma
  • Myeloma
  • Hematological malignancies

Market, By End-user

• Hospitals
• Specialty clinics
• Cancer research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa